T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott; Yung‐Jue Bang; Sarina A. Piha‐Paul; Albiruni R. Abdul Razak; Jaafar Bennouna; Jean‐Charles Soria; Hope S. Rugo; Roger B. Cohen; Bert H. O’Neil; Janice M. Mehnert; Juanita Lopez; Toshihiko Doi; Emilie M.J. van Brummelen; Răzvan Cristescu; Ping Yang; Kenneth Emancipator; Karen Stein; Mark Ayers; Andrew K. Joe; Jared Lunceford

doi:10.1200/jco.2018.78.2276

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

A T-cell--inflamed GEP, PD-L1 expression, and TMB predicted response to pembrolizumab in multiple tumor types. These biomarkers (alone/in combination) may help identify patients who have a higher likelihood of response to anti-PD-1 therapies across a broad spectrum of cancers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ott et al. (2018) studied this question.

synapsesocial.com/papers/69d6c45139aaaf0da5ab35ab https://doi.org/10.1200/jco.2018.78.2276

View at Publisher

Ask AI

Bookmark

Share

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ask about this paper

Abstract

Discussion

Cite This Study

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading